Systematic Review of Oral Therapy for the Treatment of Symptoms of Bladder Pain Syndrome: The Brazilian Guidelines

Revisão sistemática sobre terapia oral para tratamento dos sintomas da síndrome da bexiga dolorosa: as diretrizes brasileiras

Thaís Guimarães dos Santos1,2  Isabela Albuquerque Severo de Miranda2  Christiana Campani Nygaard2  Lucas Schreiner1,2  Rodrigo de Aquino Castro3  Jorge Milhen Haddad4

1 School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil  2 Sector of Gynecology, Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil  3 School of Medicine, Universidade Federal de São Paulo, SP, Brazil  4 Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, SP, Brazil

Address for correspondence Thaís Guimarães dos Santos, PhD, (e-mail: thaisgsantos@gmail.com).

Interstitial cystitis (IC), including bladder pain syndrome (BPS), is a chronic and debilitating disease that mainly affects women. It is characterized by pelvic pain associated with urinary urgency, frequency, nocturia and negative urine culture, with normal cytology. In 2009, the Society for Urodynamics and Female Urology (SUFU) defined the term IC/BPS as “an unpleasant sensation (pain, pressure, and discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than 6 weeks duration, in the absence of infection or other identifiable causes.” This is the definition used by the American Urological Association (AUA) in the most recent guidelines on IC/BPS. Interstitial cystitis may be sufficiently severe to have a devastating effect on the quality of life, but it may also be associated with moderate symptoms whose effects are less debilitating. Although there are several clinical trials to assess oral and intravesical therapies, the treatment for IC remains far from ideal. This systematic assessment evaluates published randomized clinical trials on oral medications used to treat symptoms of BPS. This study was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) method. Two independent reviewers screened the studies to determine their inclusion or exclusion and to perform the methodological analysis. The inclusion criteria included randomized studies published between April of 1988 and April of 2016 that used oral medications to treat symptoms of BPS or IC. According to the systematic review
Resumo

Cistite intersticial (IC), incluindo a síndrome da bexiga dolorosa (SBD), é uma doença crônica e debilitante que afeta principalmente mulheres. É caracterizada por dor pélvica associada à urgência miccional, frequência urinária, noite e exame cultural de urina negativo, com citologia normal. A cistite intersticial pode ser suficientemente severa para ter um efeito devastador na qualidade de vida, mas também pode estar associada a sintomas moderados e menos debilitantes. Embora existam vários ensaios clínicos para avaliar terapias orais e intravesicais, o tratamento para IC permanece longe do ideal. Esta revisão sistemática avaliou ensaios clínicos randomizados publicados sobre medicamentos orais usados para tratar sintomas de SBD. Este estudo foi realizado de acordo com o método preferred reporting items for systematic reviews and meta-analyses (PRISMA). Dois revisores independentes examinaram os estudos para determinar sua inclusão ou exclusão e para realizar a análise metodológica. Os critérios de inclusão foram: ensaios clínicos randomizados publicados entre abril de 1988 e abril de 2016 que usaram medicações orais no tratamento dos sintomas da SBD ou CI. De acordo com a revisão sistemática realizada, a melhor opção de medicação oral para o tratamento dos SBD é o pentosano polissulfato sódico. No entanto, esta droga não está disponível no Brasil. A amitriptilina administrada por via oral é um tratamento eficaz para SBD e deve ser oferecida como primeira escolha.

Descritores

- síndrome da bexiga dolorosa
- cistite intersticial
- terapia oral

Introduction

Interstitial cystitis (IC), including bladder pain syndrome (BPS), is a chronic and debilitating disease that mainly affects women. It is characterized by pelvic pain associated with urinary urgency, frequency, nocturia and negative urine culture, with normal cytology.¹ ² There is no consensus on the physiopathology, etiology and IC classification, resulting in diagnoses made by clinical exclusion rather than by objective measures. Physiopathological alterations may result in a process of epithelial cell dysfunction, C nerve fiber activation and mast cell proliferation, ultimately leading to a worsening condition and tissue damage, scarring, fibrosis and neuropathic pain.² The IC diagnosis presents several clinical phenotypes, most likely with different combinations of etiologies, symptom complexes and associated comorbidities.³ Interstitial cystitis may be sufficiently severe to have a devastating effect on the quality of life, but it may also be associated with moderate symptoms whose effects are less debilitating.⁴ ⁶

Some studies have shown that women with IC may have a higher prevalence of several organisms in the urinary microbiota of the lower urinary tract, even with negative culture (for bacteria). In addition, the reports of a decrease in symptoms following the administration of antibiotics in some cases of IC suggest that bacteria may have a role in the symptoms of this disease.⁷

Although there are several clinical trials to assess oral and intravesical therapies for the syndrome, the treatment for IC remains far from ideal.⁶ Moreover, many of the existing oral treatments are ineffective in patients with IC, and patients might require multimodal treatment to relieve symptoms.⁴

Recent studies have suggested that nitric oxide (NO) may play a role in the etiology of IC. Nitric oxide is the product of L-arginine oxidation and has many physiological functions, but two are considered important in the bladder and, potentially, in IC. First, it acts as an antagonist of smooth muscle contraction, promoting muscle relaxation; and second, it seems to inhibit the degranulation of mast cells, decreasing the associated inflammatory reactions. Women with IC have significantly less NO synthesis activity in their urine than normal control subjects.⁸ ⁹

Amitriptyline is an option frequently used to treat patients with IC. It has at least three major pharmacological actions. It has central and peripheral anticholinergic action, and it blocks the active transport system in the presynaptic nerve ending, which is responsible for the reuptake of serotonin and noradrenaline. The sedative properties may be related to its antihistaminic properties and may explain the potential benefits observed in patients with IC.⁵

Other drugs, such as gabapentin, are being studied with a specific focus on pain treatment. Pentosan polysulfate sodium (PPS) is the only FDA-approved oral therapy for IC. The mechanism of action for PPS is not completely understood, but a widely accepted theory is that it replaces the damaged segments of the glycosaminoglycan layer, which protects the bladder against the corrosive effects of urine and bacteria. It is believed that intravesical therapy, compared with oral therapy alone, may provide the benefit of establishing a higher drug
concentration directly into the bladder, with a minimal risk of systemic side effects. Thus, the PPS instilled directly into the bladder could accelerate the resolution of IC symptoms.4

The objective of this systematic review is to evaluate published randomized clinical trials on oral medications used to treat symptoms of BPS, analyzing group of patients, interventions, comparisons and outcomes of each study.5

Methods

A systematic review was performed using the PubMed, Embase and Lilacs databases. The following terms were used to search clinical trials that included female patients: interstitial cystitis or painful bladder syndrome or bladder pain syndrome or pelvic pain and pharmacological treatment.

This study was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement.10 Two independent reviewers screened the studies to determine inclusion or exclusion and to perform the methodological analysis.

The inclusion criteria comprised randomized studies published between April of 1988 and April of 2016 that used oral medications to treat symptoms of BPS or IC. We included trials that compared an oral treatment for BPS versus another oral, intravesical or placebo treatment. The oral medication must have been used in at least one arm of the study and the methodology must have been clearly described.

Studies that were not published in English, Portuguese or Spanish and studies that did not show results related to the symptoms of BPS or IC were excluded.

The articles were subdivided into groups according to the drug used. The results of each group were assessed by comparing the initial assessment to the final clinical outcome data.

All articles were scored according to the Jadad scale.11 The Jadad scale consists of three topics, which are directly related to bias reduction and are centered on internal validity. All questions have a yes/no option. The Jadad Scale has a five-point quality scale: three single points for “yes” responses and two additional points for appropriate methods of randomization and allocation concealment.11

Results

Initially, 45 articles were identified in the database search. Twenty publications were fully analyzed, and from these studies, 13 randomized studies were selected for inclusion. The studies were divided into subgroups, according to the drug studied: 5 studies assessed PPS, 2 studies assessed amitriptyline, 2 studies assessed L-arginine, and 4 studies assessed other drugs (sildenafil, antibiotics, cyclosporine, dimethyl sulfoxide [DMSO] and PD-0299685). The study selection process is illustrated in a PRISMA flowchart presented in Fig. 1.

L-Arginine

Two studies that used L-arginine to treat BPS were found. Korting et al2 tested a dose of 1,500 mg daily for 3 months compared with placebo. The four primary outcome measures used to assess the effect of L-arginine treatment on IC symptoms were a voiding diary, a secondary outcome measure, a symptom score and a Likert scale. According to the intention-to-treat

![Flowchart](image-url)

Fig. 1 Flowchart demonstrating the process of searching, screening, and selecting eligible studies.
(ITT) analysis, 22% of the patients (6 of 27) in the l-arginine group, and 12% (3 of 26) of the ones in the placebo group were clinically improved at the end of the trial ($p = 0.31$). The ITT analysis showed no significant differences between the groups in the voiding diary results evaluating frequency and nocturia, secondary outcome measure, symptom score or the Likert scale. The trial was completed by 21 of 27 patients in the l-arginine group, and 25 of 26 in the placebo group. According to the protocol analysis, 29% (6 out of 21) of the patients in the l-arginine group and 8% (2 out of 25) of those in the placebo group were clinically improved by the end of the trial ($p = 0.07$). A Likert scale showed greater global improvement in the l-arginine group (48%, 10 of 21) compared with the placebo group (24%, 6 of 25) at 3 months ($p = 0.05$), with a decrease in pain intensity ($p = 0.041$), and tendency toward improvement in urgency ($p = 0.06$) and frequency of pain ($p = 0.09$). Using an ITT analysis of the outcome measures, there were no significant differences between the groups after the initiation of l-arginine or placebo. According to the per-protocol analysis, the Likert scale showed significant improvement in the l-arginine group compared with the placebo group. As per the Likert scale, the l-arginine group had significantly greater improvement in pain intensity and in all symptoms combined (global improvement) at 3 months. The ITT analysis includes all patients, regardless of withdrawal from the trial for assigned group analysis. The per-protocol analysis includes only those patients who adhere to the protocol during the study. According to the per-protocol analysis, the use of l-arginine significantly decreased the IC pain intensity ($p = 0.04$) and the global scores on a Likert scale ($p = 0.05$) (Table 1).

Cartledge et al\(^5\) tested a daily dose of 2,400 mg of l-arginine for 4 weeks and compared the results with those of placebo. The primary endpoint of the study was a change in the IC symptoms index (ICSI) score. There was no difference between the group receiving l-arginine and the placebo in the studied outcomes (ICSI score, symptoms score and voiding diary). The ICSI score recorded from patients after 4 weeks of l-arginine use was 7.5% lower than the mean value calculated at baseline ($p < 0.05$). Although lower than the mean ICSI score recorded from patients on placebo, the difference was not significant ($p = 0.16$), and even though the improvement in the ICSI score over baseline after 4 weeks of treatment with l-arginine was statistically significant, the effect was not considerably better than that with placebo (Table 1).

### Other Drugs

The following four treatments were tested: PD-0299685, cyclosporine A, sildenafil and multiple antibiotics. The PD-0299685 is an agonist of the α2/δ subunit of the voltage-dependent calcium channel. The α2/δ subunit of voltage-gated calcium ion channels mediates afferent pain fibers and is implicated in chronic pain. There is a small number of uncontrolled reports suggesting that, as the α2/δ ligand may have efficacy in refractory genitourinary pain and IC/BPS. Nickel et al\(^3\) tested PD-0299685 at daily doses of 30 and 60 mg and compared the results to those of the placebo group for a 12-week period; PD-0299685 failed to show a significant benefit over the placebo and presented poor tolerability (Table 2).

Sairanen et al\(^9\) compared a cyclosporine A (CyA) dose of 1.5 mg/kg, twice per day, with 100 mg of PPS, 3 times per day for 6 months. Cyclosporine A was superior to PPS in all clinical studied outcome parameters measured at 6 months. The micturition frequency in 24 hours was significantly reduced in the CyA arm compared with the PPS arm. The clinical response rate (according to global response assessment) was 75% for CyA compared with 19% for PPS ($p < 0.001$). There were more adverse events in the CyA arm than in the PPS arm (Table 2).

Chen et al\(^12\) tested sildenafil at daily doses of 25 mg and compared these results to those of a placebo for a 3-month period. Sildenafil showed significant superiority over the placebo on all studied outcomes (Table 2). Warren et al\(^7\) tested the combination of using a 300 mg per day dose of rifampicin for 18 weeks with a sequential therapy of antibiotics, 3 weeks each, using the following doses: 100 mg doxycycline twice per day; 250 mg erythromycin four times per day; 500 mg metronidazole four times per day; 300 mg clindamycin four times per day; 500 mg amoxicillin three times per day and 250 mg ciprofloxacin twice per day in comparison to placebo. The treatment did not significantly improve the symptoms, compared with placebo, and showed significant increase in dropout and side effects (Table 2).

### Amitriptyline

Two studies using amitriptyline to treat BPS were included (Table 3). Foster et al\(^8\) performed a study with 271 participants, in which both groups received information on behavioral modifications, and compared amitriptyline versus placebo. The medication was increased on the sixth week from 10 to 75 mg/day. The primary outcome was the assessment of the

### Table 1 Outcomes of l-arginine in the treatment of painful bladder syndrome

<table>
<thead>
<tr>
<th>First Author/Year</th>
<th>n</th>
<th>Groups</th>
<th>Outcomes Measured</th>
<th>Results</th>
<th>Significance between groups</th>
<th>Jadad Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cartledge et al</td>
<td>16</td>
<td>l-arginine x placebo</td>
<td>ICSI score</td>
<td>Significant improvement compared with initial assessment. No difference between groups.</td>
<td>$p = 0.16$</td>
<td>3</td>
</tr>
<tr>
<td>Korting et al</td>
<td>53</td>
<td>l-arginine x placebo</td>
<td>Symptoms Score</td>
<td>No difference between groups.</td>
<td>$p = 0.31$ (intention to treat)</td>
<td>5</td>
</tr>
</tbody>
</table>

Abbreviation: ICSI, interstitial cystitis symptoms index.
### Table 2 Outcomes of Amitriptyline in the treatment of painful bladder syndrome

<table>
<thead>
<tr>
<th>First Author/Year</th>
<th>Drug tested</th>
<th>n</th>
<th>Groups</th>
<th>Outcomes Measured</th>
<th>Results</th>
<th>Significance between groups</th>
<th>Jadad Scale^11 score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nickel et al (2012)^3</td>
<td>PD-0.299685</td>
<td>161</td>
<td>PD-0.299685 30 mg x PD-0.299685 60 mg x placebo</td>
<td>ICSI score, severity score of pain worsening</td>
<td>No difference between groups and placebo.</td>
<td>p = 0.08</td>
<td>2</td>
</tr>
<tr>
<td>Sairanen et al (2005)^9</td>
<td>Cyclosporine A</td>
<td>64</td>
<td>Cyclosporine A x Pentosan polysulfate</td>
<td>daily micturition frequency, Volume voided, Nocturia, Scale of pain</td>
<td>Significant improvement in parameters regarding pentosan polysulfate</td>
<td>p &lt; 0.01</td>
<td>3</td>
</tr>
<tr>
<td>Chen et al (2014)^12</td>
<td>Sildenafil</td>
<td>48</td>
<td>Sildenafil x Placebo</td>
<td>Voiding diary, ICSI score, ICPI, Visual analog scale, Urodynamic parameters, Symptoms global improvement rate</td>
<td>Significant improvement in parameters regarding placebo.</td>
<td>p &lt; 0.05</td>
<td>3</td>
</tr>
<tr>
<td>Warren et al (2000)^7</td>
<td>Antibiotics</td>
<td>50</td>
<td>Antibiotics x Placebo</td>
<td>Semi-quantitative assessment of bladder pain</td>
<td>No significant difference in global improvement between groups.</td>
<td>p = 0.14</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: GRA, global response assessment; ICPI, Interstitial Cystitis Problem Index; ICSI, interstitial cystitis symptoms index.

### Table 3 Outcomes of other drugs in the treatment of painful bladder syndrome

<table>
<thead>
<tr>
<th>First Author/Year</th>
<th>n</th>
<th>Groups</th>
<th>Outcomes Measured</th>
<th>Results</th>
<th>Significance between groups</th>
<th>Jadad Scale^11 score</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Ophoven et al (2004)^3</td>
<td>50</td>
<td>Amitriptyline 25 to 100 mg/day x Placebo</td>
<td>ICSI, Visual pain scale</td>
<td>Significant improvement in pain symptoms and urgency intensity scores.</td>
<td>p = 0.05 (score) p &lt; 0.001 (pain/urgency)</td>
<td>4</td>
</tr>
<tr>
<td>Foster et al (2010)^6</td>
<td>271</td>
<td>Amitriptyline 10 to 75 mg/day x Placebo</td>
<td>GRA, ICSI, SF-36, FSFI</td>
<td>Group using Amitriptyline, at least 50 mg/day, had significant improvement.</td>
<td>p &lt; 0.01 (for dose of at least 50 mg/day)</td>
<td>3</td>
</tr>
</tbody>
</table>

Abbreviations: DMSO, dimethyl sulfoxide; FSFI, female sexual function index; GRA, global response assessment; ICSI, interstitial cystitis symptoms index; SF-36, health related quality of life index.
global response based on the improvement of symptoms after 12 weeks of treatment. The subgroup of patients that received a dose of at least 50 mg amitriptyline demonstrated a significantly higher response than that obtained with placebo (p < 0.01).6

Van Ophoven et al1 tested amitriptyline at a dose of 25 to 100 mg and compared these effects to placebo. There was significant change in the symptoms score, and a significant improvement in pain and urgency was observed when the treated group was compared with placebo. The use of amitriptyline for 4 months was considered safe and effective for the treatment of IC.1

Pentosan Polysulfate Sodium

Five randomized studies assessed the use of PPS in the treatment of symptoms of IC/BPS, and their most relevant results are described in Table 4.

The studies included a total of 1,084 patients. The largest series was published by Nickel et al4 in 2005, and included 380 cases. Three doses of PPS were tested (300, 600, and 900 mg) for 32 weeks. The ICSI score average improved significantly during the 32 weeks for all dosages. Thus, there was relevant clinical improvement with the three dosages. However, the treatment duration appeared to be more important than the dosage.4

Mulholland et al13 compared the results of PPS use to those of placebo over 3 months of treatment. Global improvement higher than 25% was reported by 28% of patients treated with PPS and by only 13% of patients who received placebo (p = 0.03). In this study, PPS was considered as safe and more effective than placebo.13

Sant et al14 published a study designed to assess PPS and hydroxyzine. The primary outcome was the global response assessment. The treatment response rate with hydroxyzine was 31% and there was a 20% response for the untreated group (p = 0.26). With PPS, the response was 34% and in the untreated group it was 18% (p = 0.064). The low global response rate to PPS and hydroxyzine suggests that none of these therapies can provide benefits to most patients with IC.14

Nickel et al.15 tested doses of 100 and 300 mg of PPS and compared these effects to those of the placebo group for 24 weeks. There was no difference between the groups receiving PPS and placebo regarding the primary outcome (30% of reduction of ICSI total score from the initial to final assessment).15

David et al16 assessed 41 women diagnosed with IC who received intravesical PPS associated with oral PPS or placebo associated with oral PPS for 6 weeks. The use of intravesical PPS combined with oral PPS was the safest and most effective therapeutic option.16

The studies included were scored according to the Jadad Scale. Only three studies received the maximum score on this scale, which showed high quality; nine studies scored three or lower and one study scored four.

Discussion

The product of L-arginine oxidation is NO. Although NO may have a potential effect on the etiology of BPS, the clinical results of L-arginine in the treatment of this pathology were no better than placebo.2,8 Among the drugs with very few studies in the

---

Table 4

<table>
<thead>
<tr>
<th>First Author/Year</th>
<th>n</th>
<th>Groups</th>
<th>Outcomes Measured</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nickel et al (2014)</td>
<td>368</td>
<td>PPS 100 mg x placebo</td>
<td>No significant difference in symptoms.</td>
<td></td>
</tr>
<tr>
<td>Nickel et al (2005)</td>
<td>380</td>
<td>PPS 300 mg x placebo</td>
<td>Significant difference in symptoms.</td>
<td></td>
</tr>
<tr>
<td>Mulholland et al (1990)</td>
<td>110</td>
<td>PPS 300 mg x placebo</td>
<td>Significant difference in symptoms.</td>
<td></td>
</tr>
<tr>
<td>Sant et al (2003)</td>
<td>121</td>
<td>Combined therapy (PPS + hydroxyzine) x placebo</td>
<td>Significant difference in symptoms.</td>
<td></td>
</tr>
<tr>
<td>Davis et al (2008)</td>
<td>41</td>
<td>Intravesical PPS + oral PPS</td>
<td>Significant difference in symptoms.</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: GRA, global response assessment; ICSI, interstitial cystitis symptoms index; PORS, patient overall rating of symptoms index; PUF, pelvic pain and urgency/frequency questionnaire; SF-36, health related quality of life index.
management of BPS, sildenafil at a low dose and CyA showed promising initial results, but these results need to be verified by further studies with larger groups of individuals.5,12

According to Foster et al.,6 amitriptyline plus an education and behavioral modification program did not significantly improve the symptoms. The adverse effects were acceptable, but the adherence to treatment with higher doses was low. The study also suggests that amitriptyline may be beneficial just in the group that can achieve a daily dose of 50 mg/day, although this subgroup comparison was not specified in advance.6 In the study performed by van Ophoven et al.,1 there was an improvement in symptoms, and it was also confirmed that amitriptyline showed a significant improvement in the urinary urgency symptom. These authors describe that, based on the results of this study, they recommended using amitriptyline as a first-line therapy for IC in their institution.1

With regard to PPS assessment, the studies showed heterogeneous outcomes. Three series included a dose of 300 mg/day in their assessments. In two of the series, this dose was compared with placebo, and the results were conflicting. In the study performed by Nickel et al (2014),15 there was no difference between the group that received 300 mg/day of PPS and the group that received placebo on the primary outcome, which was defined in this study as a 30% reduction of the ICSI total score from the initial to final assessment. In the series published by Mulholland et al.,13 with the same dose of 300 mg/day, PPS was more effective than placebo.13,15

However, due to the limitations caused by the study design, early termination, inclusion criteria and high dropout rate, Nickel et al (2014)15 reported that they do not believe that their study can be used to justify the abandonment of one of the few medications with significant clinical trials in the treatment of IC/BPS. They also report that PPS is most likely the best component of an overall therapeutic strategy as described in the American Urological Association (AUA) guidelines.15

Although antihistamines are widely used in the treatment of BPS, studies that assess their exclusive use were not found in our search. Only one study evaluating hydroxyzine was found. It was not possible to perform a meta-analysis based on the assessed clinical trials due to the heterogeneity of the published studies.

Conclusion

According to the systematic review performed, we should consider PPS as one of the best options of oral drugs for the treatment of BPS symptoms. However, this drug is not an available option in Brazil. Orally administered amitriptyline is an efficacious medical treatment for BPS and should be the first treatment offered.

References


